[News Focus] Why Kim Jong-un spotlights mothers
Korean students outperform OECD average amid pandemic havoc: data
LG Display launches voluntary redundancy program in efficiency drive
‘Korea could go extinct without proper immigration policy’: minister
S. Korea, US, Japan to discuss regional security issues: White House
Celltrion’s COVID-19 treatment gets safety nod in AustraliaBy Kan Hyeong-woo
Published : Feb. 7, 2022 - 13:53
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
S. Korea eyes chip alliance with Netherlands
SK carries out complete reshuffle of top brass
Suneung without 'killer questions' still not easy, results show